This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 34(12), 2213-2219
Citation
Leder, Benjamin Z; Zapalowski, Carol; Hu, Ming-Yi; Hattersley, Gary; Lane, Nancy E; Singer, Andrea J; Dore, Robin K. (2019). Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 34(12), 2213-2219. https://doi.org/10.1002/jbmr.3848